Evidence map›Paper›PMID 21225629›Full record

ArticleInternational journal of cancer2011

MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.

Riina Kuuselo, Kimmo Savinainen, Saana Sandström, Reija Autio, Anne Kallioniemi

Abstract read
In one paragraph

Article in International journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Biallelic MED29 variants cause pontocerebellar hypoplasia with cataracts.European journal of human genetics : EJHG · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Transcription regulation by the Mediator complex.Nature reviews. Molecular cell biology · 2018
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Mediator and human disease.Seminars in cell & developmental biology · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Riina KuuseloInstitute of Medical Technology, University of Tampere and Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland.
Kimmo Savinainen
Saana Sandström
Reija Autio
Anne Kallioniemi
Tampere University · FITampere University · FITampere University Hospital · FI

Funding

Validation of Amplified Genes in Pancreatic CancerP01CA109552 · NCI · TRANSLATIONAL GENOMICS RESEARCH INST · PI VON HOFF, DANIEL D · 2005 to 2009
$15.2M
NCI NIH HHS P01 CA109552
6 · The paper itself

Abstract

Mediator complex subunit 29 (MED29) is part of a large multiprotein coactivator complex that mediates regulatory signals from gene-specific activators to general transcription machinery in RNA polymerase II mediated transcription. We previously found that MED29 is amplified and overexpressed in pancreatic cancer and that MED29 silencing leads to decreased cell survival in PANC-1 pancreatic cancer cells with high MED29 expression. Here we further demonstrate decreased migration, invasion and colony formation in PANC-1 cells after MED29 silencing. Unexpectedly, lentiviral-based overexpression of MED29 led to decreased proliferation of NIH/3T3 cells as well as MIAPaCa-2 pancreatic cancer cells with low endogenous expression. More importantly, subcutaneous inoculation of the MED29-transduced pancreatic cancer cells into immuno-compromised mice resulted in dramatic tumor suppression. The mock-control mice developed large tumors, whereas the animals with MED29-xenografts showed both decreased tumor incidence and a major reduction in tumor size. Gene expression analysis in the MED29-transduced pancreatic cancer cells revealed differential expression of genes involved in control of cell cycle and cell division. The observed gene expression changes are expected to modulate the cell cycle in a way that leads to reduced cell growth, explaining the in vivo tumor suppressive phenotype. Taken together, these data implicate MED29 as an important regulator of key cellular functions in pancreatic cancer with both oncogenic and tumor suppressive characteristics. Such a dualistic role appears to be more common than previously thought and is likely to depend on the genetic background of the cancer cells and their surrounding environment.

Indexed as

Genes, Tumor SuppressorOncogenesBiomarkers, TumorBlotting, WesternCell AdhesionCell Line, TumorCell MovementCell ProliferationGene Expression ProfilingHumansImmunoenzyme TechniquesMediator ComplexOligonucleotide Array Sequence AnalysisPancreatic NeoplasmsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerBiomarkers, TumorMED29 protein, humanMediator ComplexRNA, MessengerRNA, Small Interfering

Identifiers

PMID21225629
PMCPMC3118263
OpenAlexW1993429678

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.